You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
New insights into the molecular profile of lung adenocarcinoma and implications for therapy
|
|---|---|
| Published in |
Expert Review of Anticancer Therapy, March 2015
|
| DOI | 10.1586/14737140.2015.1017472 |
| Pubmed ID | |
| Authors |
Bharath Ganesh, Siddhartha Devarakonda, Ramaswamy Govindan |
| Abstract |
Lung cancer is a molecularly heterogeneous disease. The advent of next-generation sequencing techniques has significantly advanced our understanding of the complex molecular underpinnings of lung cancer. Furthermore, the development of targeted therapies has significantly altered the landscape of lung cancer therapy over the past decade. There is hence an increasing interest in developing a classification system that guides clinical management and also incorporates relevant genomic information. Here, we highlight the molecular features of lung adenocarcinoma as highlighted by several independent groups, and more recently The Cancer Genome Atlas and discuss their potential clinical significance. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 13 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 23% |
| Student > Master | 2 | 15% |
| Other | 1 | 8% |
| Student > Doctoral Student | 1 | 8% |
| Student > Ph. D. Student | 1 | 8% |
| Other | 3 | 23% |
| Unknown | 2 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 4 | 31% |
| Medicine and Dentistry | 4 | 31% |
| Environmental Science | 1 | 8% |
| Agricultural and Biological Sciences | 1 | 8% |
| Unspecified | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 2 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 May 2015.
All research outputs
#17,750,476
of 22,794,367 outputs
Outputs from Expert Review of Anticancer Therapy
#695
of 1,053 outputs
Outputs of similar age
#176,333
of 258,843 outputs
Outputs of similar age from Expert Review of Anticancer Therapy
#8
of 12 outputs
Altmetric has tracked 22,794,367 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,053 research outputs from this source. They receive a mean Attention Score of 3.9. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 258,843 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.